News blog

Tiziana Life Sciences

• BY: Andrew Hore |
• POSTED: 24/04/2014 |

Shares in Tiziana Life Sciences ended the first day of trading at more than double the price at which the shares were issued to acquire the business.

Tiziana reversed into Alexander David Investments and the all share deal was valued at £7.5m at 12p a share. A placing raised a further £2m at the same share price. The share price started the day at 16.5p and it rose during the day and ended at a high of 27.5p a share. This values Tiziana at £25m.

Tiziana discovers and develops molecules with a focus on metastatic cancers, which are cancers that have spread to other parts of the body. The first development programme is for metastatic breast cancer. The technology was developed in Cardiff University and Tiziana has exercised an option to licence the B-cell Lymphoma 3 gene technology being developed at the university. Tiziana holds worldwide rights.

Download the latest AIM Journal from http://www.hubinvest.com/AIMPDFApril2014_55.pdf